April 6th 2024
New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.
Disparities in Statin Use for ASCVD Unexplained by Disease Severity, Structural Factors
July 24th 2023A cross-sectional analysis suggests disparities in statin use for several race–ethnicity–gender groups were not explained by ASCVD severity or structural factors, including socioeconomic status and health insurance.
Statin Therapy Could Reduce Cardiovascular Events in People with HIV
July 24th 2023New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.
Study Identifies Potential Link Between Gut Microbiome and Atherosclerosis
July 12th 2023Using data from more than 8500 patients from a bioimaging study, investigators took a deep dive into potential associations between gut microbiome and subclinical atherosclerosis in adults without a history of cardiovascular disease
FDA Approves Colchicine Tablets for Reducing Cardiovascular Risk
June 20th 2023Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.
Healthy Beverage Choices May Lower Mortality Risk in Adults with Diabetes
April 20th 2023An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.
A Potential New Role for Colchicine: Unraveling Inflammation in ASCVD
April 7th 2023The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.
Transcatheter Arterialization Could Revolutionize Treatment of Limb-Threatening Ischemia
March 31st 2023Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.
Subclinical, Asymptomatic Atherosclerosis Linked to 8-Fold Increase in Myocardial Infarction
March 28th 2023An analysis of more than 9000 adults aged 40 and older without known cardiovascular disease is shedding new light on the risk of myocardial infarction and mortality associated with subclinical coronary atherosclerosis.
Statin Use for ASCVD Prevention Lower Among Black, Hispanic Individuals
March 22nd 2023An analysis of NHANES from 2013 - March 2020 suggest individuals with an indication for statin therapy for primary prevention based on 10-year risk saw low overall use across risk categories and race and ethnicity strata.